Promising new 'antigene' therapy

Oct 21, 2010
Oligonucleotides, edited by John Rossi, Ph.D., and C.A. Stein, M.D., Ph.D., from the Department of Oncology at Albert Einstein-Montefiore Cancer Center, is an authoritative, peer-reviewed journal published 6 times a year in print and online that focuses on synthetic oligonucleotides, including RNA, DNA, and ribozymes, and their effects on gene expression at the RNA and DNA levels both in vitro and in vivo. It represents a forum for basic research and applied therapeutics for the purpose of developing new concepts and experimental approaches to understanding and modulating gene activity. Oligonucleotides is the official journal of the Oligonucleotide Therapeutics Society (http://www.myots.org). Tables of content and a free sample issue may be viewed online at www.liebertpub.com/oli. Credit: Mary Ann Liebert Inc., publishers

Antigene therapy is a promising new treatment strategy that uses a DNA-based drug to pinpoint light energy to a target gene shutting down its activity. A review article published online ahead of print in Oligonucleotides, a peer-reviewed journal published by Mary Ann Liebert, Inc., details the possibilities and challenges for the clinical application of this novel photo-activated DNA modulating approach.

Netanel Kolevzon and Eylon Yavin, from The Hebrew University of Jerusalem (Israel), describe the mechanism behind antigene therapy in the article "Site-Specific DNA Photocleavage and Photomodulation by Oligonucleotide Conjugates." They review the development of triplex-forming DNA-based drugs capable of up-regulating or inhibiting gene expression in a highly targeted and selective manner.

Unlike existing antisense therapies that target RNA, an antigene drug is a triplex-forming oligonucleotide that recognizes and attaches directly to a specific DNA sequence. By attaching a photoreactive agent to the antigene and delivering light energy to the attachment site, the light-sensitive drug complex becomes activated, triggering a cleavage or cross-linking reaction. This photo-induced, site-specific effectively silences the .

"Many obstacles lay ahead before this approach may reach the clinic," caution the authors. However, if antigene therapy proves successful at blocking , "many diseases that are currently incurable or otherwise treatable with limited success could be potentially relevant targets for such an approach," they conclude.

"This is a clever and potentially powerful approach to targeted regulation of gene expression," says John Rossi, PhD, Co-Editor-in-Chief of Oligonucleotides and Professor in the Department of Molecular Biology, Beckman Research Institute of the City of Hope (Duarte, CA).

Explore further: NIH issues finalized policy on genomic data sharing

More information: The article is available free online at www.liebertpub.com/oli

Provided by Mary Ann Liebert, Inc.

5 /5 (3 votes)
add to favorites email to friend print save as pdf

Related Stories

New DNA and RNA aptamers offer unique therapeutic advantages

Aug 05, 2009

A novel class of drugs composed of single strands of DNA or RNA, called aptamers, can bind protein targets with a high strength and specificity and are currently in clinical development as treatments for a broad range of ...

The RNA drug revolution -- a new approach to gene therapy

Jan 23, 2008

RNA interference (RNAi) represents an innovative new strategy for using small RNA molecules to silence specific genes associated with disease processes, and a series of review articles describing the state-of-the-art and ...

New paradigm for cell-specific gene delivery

Jun 23, 2008

Researchers from Northwestern University and Texas A & M University have discovered a new way to limit gene transfer and expression to specific tissues in animals. In studies to determine how plasmids enter the nuclei of ...

Recommended for you

NIH issues finalized policy on genomic data sharing

12 hours ago

The National Institutes of Health has issued a final NIH Genomic Data Sharing (GDS) policy to promote data sharing as a way to speed the translation of data into knowledge, products and procedures that improve health while ...

The genes behind the guardians of the airways

18 hours ago

Dysfunctions in cilia, tiny hair-like structures that protrude from the surface of cells, are responsible for a number of human diseases. However the genes involved in making cilia have remained largely elusive. ...

Cancer leaves a common fingerprint on DNA

Aug 25, 2014

Regardless of their stage or type, cancers appear to share a telltale signature of widespread changes to the so-called epigenome, according to a team of researchers. In a study published online in Genome Me ...

User comments : 0